Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• Assembly is a critical step in the HTV-I life cycle (Morikawa, 2003; Huseb et al., 2005; Gottliger, 2001; Freed, 1998) and generally thought to occur through the controlled polymerization of the gag polyprotein, which is transported to the plasma membrane where the assembly takes place and the virus particles are formed and bud out as spherical immature noninfectious particles.
• AP-3 a cellular protein, directs the intracellular trafficking of gag to the MVB (Dong et al., 2005).
• maturation which is essential for the virus to become infectious, where the gag polyprotein is sequentially cleaved by the viral protease to matrix (MA), capsid (CA), nucleocapsid (NC) and p6 domains as well as two spacer proteins, SPl and SP2.
• MA viral protease to matrix
• CA capsid
• NC nucleocapsid
• SPl and SP2 two spacer proteins
• capsid plays important role in viral assembly, which is critical in HIV-I life cycle and has been considered as potential target for developing new generations of drugs against HlV-I .
• CAJ small linear peptide
• the present invention is directed to peptides from 10 to 23 amino acids long, wherein two of the amino acids are unnatural amino acids having either R OT S stereochemistry at the ⁇ - carbon, wherein the ⁇ -carbon of the unnatural amino acids comprises a methyl group and an olef ⁇ nic group, where the two olef ⁇ nic groups of the unnatural amino acids are on the same side of the ⁇ -helix and are joined to form a cross-link between the two unnatural amino acids, wherein the sequence of the amino acids of the peptide comprises (I/L/V)(T/S/A/V/C)(F/I/L/V/ ⁇ A/S)(Y/F/VL/V/M/W)(Y/F/1/L/V/MJ ⁇ ) or mimetics thereof, wherein the two unnatural amino acids replace two of the amino acids at any positions 3 amino acids apart (i and i+3), 4 amino acids apart (/ and z+4) or 7 amino acids apart (/ and r+7), and where
• the invention is further directed to methods of treating a mammal infected with a capsid- containing virus.
• the methods comprise administering the above-described pharmaceutical composition to the mammal in a manner sufficient to treat the mammal.
• the invention is directed to methods of making any of the above-described peptides.
• the methods comprise sequentially coupling the amino acids, then joining the two olefmic groups of the unnatural amino acids together using olefin metathesis.
• the present invention is also directed to the use any of the above-described peptides that can inhibit assembly of a capsid-containing virus for the manufacture of a medicament for the treatment of a mammal infected with a capsid-containing virus.
• FIG. 5 shows the effect of NYAD-I on virus-like particle (VLP) release.
• 293T cells were treated with different concentrations of NYAD-I 4 hours post-transfection with vector encoding Gag (for immature-like particles) or Gag-pol (for mature-like particles).
• the VLP-containing S- supernatant was recovered 48 hours post-transfection.
• the immature- and m release was determined by measuring p24 by ELISA (upper panel A, B) and western mot ⁇ ower panel C, D). Numbers below the blots indicate the signal intensities obtained by densitometry.
• the present invention is directed to peptides from 10 to 23 amino acids long, wherein two of the amino acids are unnatural amino acids having either R or S stereochemistry at the ⁇ - carbon, wherein the ⁇ -carbon of the unnatural amino acids comprises a methyl group and an olef ⁇ nic group, where the two olefmic groups of the unnatural amino acids are on the same side of the ⁇ -helix and are joined to form a cross-link between the two unnatural amino acids, wherein the sequence of the amino acids of the peptide comprises A/S)(Y/F/I/LA ⁇ /Nd/W)(Y/T/I/LA ⁇ /M/T) or mimetics thereof, wherein the two unnatural amino acids replace two of the amino acids at any positions 3 amino acids apart (i and i+3), 4 amino acids apart (i and ⁇ +4) or 7 amino acids apart (i and j+7), and wherein the cross-link between the two unnatural amino acids is a Cl-ClO alkyl, alkenyl
• amino acid residues for the invention peptides are the combination of the specific peptide identified by Sticht et al. (2005) having the amino acid sequence ITFEDLLD YYGP (SEQ ID NO: 1 ; CAI), along with substitutions in that sequence that were identified by Sticht et al. (2005) in the peptides that most frequently bound to the C-CANC protein used in that work (see Table 1 of Sticht et al., 2005). Also included are amino acids that are conservative substitutions for the Sticht et al. peptide.
• the peptide can enter a cell and inhibit HIV reproduction. Without being bound to any particular mechanism, it is believed that the peptide binds to the capsid domain of the HIV gag protein, preventing viral assembly and thus replication. As such, the invention peptides are expected to bind and inhibit replication of any capsid-containing virus. Thus, preferred peptides can inhibit replication of a capsid-containing virus in a cell.
• any prokaryotic, eukaryotic or archaea cell infected with a capsid-containing virus can be treated with the invention peptides.
• the method can utilize cells in culture (e.g., as in Examples), or preferably in a live multicellular organism, including any plants or animals. More preferably, the cell is part of a live vertebrate infected with the capsid-containing virus. Even more preferably, the cell is in a mammal infected with the capsid-containing virus. Still more preferably, the mammal is a human, most preferably infected with HIV.
• the invention is directed to methods of making any of the above-described peptides.
• the methods comprise sequentially coupling the amino acids, then joining the two olef ⁇ nic groups of the unnatural amino acids together using olefin metathesis. These methods are described in, e.g., Schafmeister et al., 2000; Walensky et al., 2004; United States Patent " Application Publication 2006/0008848 Al; and PCT Patent Application Publication WO 2005/044839 A2.
• the amino acids are coupled using solid phase synthesis.
• the N-terminal group of the above constrained peptide was further derivatized with ⁇ -Ala and FITC (DMF/DIEA) on the resin before the cleavage.
• ⁇ -Ala and FITC DMF/DIEA
• the linear peptide CAI did not show any activity up to 200 ⁇ M dose level.
• the CCso value in MT-2 cells was > 135 ⁇ M; and in PBMC cells was > 300 ⁇ M.
• Example 5 Hydrocarbon stapling enhanced ⁇ -helicitv of NYAD-I

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Virology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=39283347

Family Applications (1)

Country Status (8)

Cited By (18)

Families Citing this family (6)

Family Cites Families (16)

• 2007
  • 2007-10-02 EP EP07839140A patent/EP2073829B1/en not_active Not-in-force
  • 2007-10-02 EP EP20120169140 patent/EP2517720A1/en not_active Ceased
  • 2007-10-02 JP JP2009531418A patent/JP2010505831A/ja active Pending
  • 2007-10-02 WO PCT/US2007/021156 patent/WO2008045238A2/en not_active Ceased
  • 2007-10-02 CA CA002665186A patent/CA2665186A1/en not_active Abandoned
  • 2007-10-02 ES ES07839140T patent/ES2387827T3/es active Active
  • 2007-10-02 AU AU2007307254A patent/AU2007307254A1/en not_active Abandoned
  • 2007-10-02 US US12/438,414 patent/US8940864B2/en active Active
• 2009
  • 2009-02-20 ZA ZA200901248A patent/ZA200901248B/xx unknown

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events